{"meta":{"query_hash":"fddd65d259ba","filters":{"venue":"Journal of Market Access & Health Policy"},"cohort_total":11,"direct_labels_cover":0,"predictions_cover":11,"exported":11,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/fddd65d259ba","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Market+Access+%26+Health+Policy"},"results":[{"id":"W2488011870","doi":"10.3402/jmahp.v4.31463","title":"Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example","year":2016,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"CLARITY; Prioritization; Order (exchange); Plan (archaeology); Resource allocation; Health care; Resource (disambiguation); Cancer drugs; Perspective (graphical); Business; Management science; Process management; Computer science; Risk analysis (engineering); Public relations; Political science; Medicine; Drug; Economics; Pharmacology; Finance","score_opus":0.4646607408831695,"score_gpt":0.5042006085953252,"score_spread":0.03953986771215573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488011870","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013336259,0.045687474,0.0003157862,0.93308675,0.00035838157,0.0013801887,0.000098160555,0.000013940467,0.005723077],"genre_scores_gemma":[0.68964726,0.14106938,0.0007191687,0.16585845,0.001878689,0.00011559295,0.0000047146,0.000067788664,0.0006389579],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897058,0.0026278573,0.0061143795,0.00046469527,0.00019353676,0.00089371117],"domain_scores_gemma":[0.98418134,0.008578214,0.005486479,0.0006999626,0.00020301733,0.0008510099],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.05866551,0.0002457932,0.0014853365,0.0012061525,0.00026349467,0.00008102287,0.0011850906,0.00014691828,0.00023948001],"category_scores_gemma":[0.027794583,0.00019886807,0.00015123359,0.00053293514,0.000058738427,0.0007065062,0.000125705,0.00041724255,0.0002086423],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020141854,0.00025978207,0.023653854,0.0034783732,0.00013048112,0.000017544515,0.009012676,0.00027962474,0.0000018218888,0.012463632,0.5348989,0.4156019],"study_design_scores_gemma":[0.0008602258,0.00020414412,0.050564446,0.0026562205,0.0000052720197,0.00004862467,0.0006727126,0.0002006148,5.6925927e-7,0.0026156823,0.9419434,0.00022806128],"about_ca_topic_score_codex":0.1258546,"about_ca_topic_score_gemma":0.27444136,"teacher_disagreement_score":0.7672283,"about_ca_system_score_codex":0.005426099,"about_ca_system_score_gemma":0.0031500468,"threshold_uncertainty_score":0.99839187},"labels":[],"label_agreement":null},{"id":"W2551027286","doi":"10.3402/jmahp.v4.33248","title":"A training paradigm to enhance performance and safe use of an innovative neuroendovascular device","year":2016,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Traumatic Brain Injury and Neurovascular Disturbances","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; University of British Columbia","funders":"","keywords":"Computer science; Training (meteorology); Complement (music); Selection (genetic algorithm); Medical physics; Medicine; Artificial intelligence","score_opus":0.09066446744580157,"score_gpt":0.4091008253124968,"score_spread":0.3184363578666952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551027286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743389,0.000337853,0.00043324986,0.02405344,0.00012376293,0.00035366425,0.000011387806,0.000010885934,0.00033686648],"genre_scores_gemma":[0.9864908,0.0018311322,0.0021550301,0.009028346,0.00035398873,0.0000076435235,5.950224e-7,0.000023906492,0.00010859461],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975827,0.00034704994,0.0010014763,0.00022941935,0.00045558362,0.00038379242],"domain_scores_gemma":[0.9976287,0.00046574324,0.00082400267,0.00032811676,0.0003005757,0.00045289026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013436241,0.00018700796,0.000726937,0.00047315072,0.000091903574,0.000037341986,0.00025159377,0.00004551899,0.000034311848],"category_scores_gemma":[0.0013701866,0.00012146212,0.00009929579,0.0007818774,0.00011511665,0.0010944224,0.000059890404,0.0002460642,0.0000010528748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018306805,0.00020703091,0.009712001,0.0010016111,0.00020563081,0.000049365837,0.0022729004,0.000005458051,0.0011587947,0.00022611936,0.0017239861,0.9816064],"study_design_scores_gemma":[0.0019763515,0.0023940664,0.9020899,0.002122287,0.00005801807,0.0010789059,0.0000861699,0.00003988181,0.0034501462,0.0001177321,0.08640106,0.00018547005],"about_ca_topic_score_codex":0.00010526762,"about_ca_topic_score_gemma":0.000022503096,"teacher_disagreement_score":0.98142093,"about_ca_system_score_codex":0.00009180476,"about_ca_system_score_gemma":0.00082194636,"threshold_uncertainty_score":0.49530816},"labels":[],"label_agreement":null},{"id":"W2593404984","doi":"10.1080/20016689.2017.1283106","title":"Role of preliminary registry data in development of a clinical trial for an innovative device: a small but integral piece of a health policy initiative","year":2017,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Intracranial Aneurysms: Treatment and Complications","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Clinical trial; Medical physics; Health care; Data collection; Medicine; Process management; Risk analysis (engineering); Computer science; Business; Political science","score_opus":0.3481206429235412,"score_gpt":0.5495211997656897,"score_spread":0.20140055684214847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593404984","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96339923,0.0003433984,0.0002763177,0.032417472,0.00012474922,0.0018071731,0.00029335805,0.000006030222,0.0013322729],"genre_scores_gemma":[0.9864366,0.00037191348,0.010764391,0.0013188478,0.0009074058,0.000042818778,0.0000802312,0.00002379609,0.000054001084],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9944217,0.0005564612,0.0039318893,0.0002961984,0.00038108762,0.00041266298],"domain_scores_gemma":[0.98872435,0.0006538893,0.008141732,0.00096841727,0.001215718,0.00029586584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052122246,0.00022150307,0.0015944903,0.000709621,0.00019890949,0.000025251165,0.0012635347,0.0001460526,0.0000105604395],"category_scores_gemma":[0.0055349777,0.00017703506,0.00015100857,0.00048645763,0.00024697624,0.00048704795,0.0003418478,0.0005010816,2.3982537e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21482894,0.010774083,0.07060311,0.003658454,0.0008020983,0.000018241692,0.010579816,0.0000016214791,0.00016770887,0.0037609364,0.0026505354,0.6821545],"study_design_scores_gemma":[0.04584923,0.013015187,0.9317657,0.0020412551,0.00008200324,0.00011010661,0.001508004,0.00022619276,0.00027597166,0.0018006935,0.0031508734,0.00017478796],"about_ca_topic_score_codex":0.0075870263,"about_ca_topic_score_gemma":0.0014016428,"teacher_disagreement_score":0.8611626,"about_ca_system_score_codex":0.00033357926,"about_ca_system_score_gemma":0.019688519,"threshold_uncertainty_score":0.99902153},"labels":[],"label_agreement":null},{"id":"W2968568322","doi":"10.1080/20016689.2019.1650596","title":"Why “American Patients First” is likely to raise drug prices outside of the United States","year":2019,"lang":"en","type":"review","venue":"Journal of Market Access & Health Policy","topic":"Global Public Health Policies and Epidemiology","field":"Business, Management and Accounting","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blueprint; Negotiation; Drug prices; Administration (probate law); International trade; Drug pricing; Food and drug administration; Political science; International economics; Business; Economics; Public economics; Law; Actuarial science; Management","score_opus":0.07185893170955603,"score_gpt":0.4186940409292448,"score_spread":0.34683510921968874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968568322","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015047267,0.45520058,0.00002443485,0.5333653,0.002884634,0.0029444485,0.00025766616,0.00004303032,0.0037751868],"genre_scores_gemma":[0.00005205799,0.711757,0.000050221654,0.28564677,0.0022125647,0.000018630513,0.00003450646,0.000067300214,0.00016096816],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99340713,0.000511527,0.0036135286,0.00039288748,0.00078035844,0.0012945815],"domain_scores_gemma":[0.9847219,0.0010903276,0.012086493,0.00073940196,0.0011043948,0.00025748345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036945366,0.00063529797,0.0036120217,0.002268505,0.000317807,0.00026833604,0.002787729,0.00019237955,0.00016227704],"category_scores_gemma":[0.0031203474,0.0003905732,0.00082557584,0.0042433646,0.00016193421,0.00086916453,0.0012426154,0.00089685176,0.0000453064],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004307888,0.0000949258,0.0014955772,0.026893338,0.0001074411,8.165772e-7,0.000092174676,0.000054063035,6.913786e-10,0.00016251669,0.84800935,0.12304675],"study_design_scores_gemma":[0.00037770817,0.00007698002,0.004161497,0.0071014557,0.0001903905,0.0000053660374,0.00006472647,0.0000531633,6.5310997e-9,0.00014423135,0.9875319,0.0002925756],"about_ca_topic_score_codex":0.1901135,"about_ca_topic_score_gemma":0.0009085359,"teacher_disagreement_score":0.25655642,"about_ca_system_score_codex":0.00062939734,"about_ca_system_score_gemma":0.0016550741,"threshold_uncertainty_score":0.9998546},"labels":[],"label_agreement":null},{"id":"W2999237747","doi":"10.1080/20016689.2020.1715536","title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","year":2020,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Biomedical Ethics and Regulation","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Payment; European union; Business; Quarter (Canadian coin); Product (mathematics); Health care; European market; Medicine; Marketing; Finance; Economic growth; Economics; International trade; Geography","score_opus":0.0599014430613446,"score_gpt":0.43239230961009045,"score_spread":0.37249086654874586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999237747","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2167749,0.004645938,0.0004009095,0.77681184,0.00017100814,0.00078220497,0.000013920368,0.000006844671,0.00039242097],"genre_scores_gemma":[0.9497097,0.0051930025,0.0012992818,0.043338194,0.000366615,0.00001352551,0.0000037460297,0.000022976117,0.000052951855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971475,0.00068733416,0.0011156667,0.00014653409,0.0006129877,0.00028998344],"domain_scores_gemma":[0.9973633,0.0007750699,0.0011495645,0.00017949878,0.00033644043,0.00019609949],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003910298,0.00014639224,0.00050764234,0.00023669387,0.00007672349,0.000037673144,0.0003182168,0.000081239945,0.000054829132],"category_scores_gemma":[0.00090573967,0.00008447942,0.000111548674,0.00045719548,0.00026888115,0.00018911377,0.000045925823,0.0004534147,3.8325663e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045309227,0.0046190834,0.31978717,0.011129123,0.0011006029,0.0003090386,0.31338692,0.00039801878,0.010132738,0.003850128,0.036183253,0.2537947],"study_design_scores_gemma":[0.014432713,0.002120349,0.69175684,0.00088222965,0.00009121653,0.000025995447,0.0100251185,0.0008271438,0.0017506253,0.0005343249,0.27730352,0.0002499049],"about_ca_topic_score_codex":0.0008304585,"about_ca_topic_score_gemma":0.000120509576,"teacher_disagreement_score":0.73347366,"about_ca_system_score_codex":0.00020963854,"about_ca_system_score_gemma":0.0013553067,"threshold_uncertainty_score":0.34449705},"labels":[],"label_agreement":null},{"id":"W3193864401","doi":"10.1080/20016689.2021.1964791","title":"Accelerating patient access to oncology medicines with multiple indications in Europe","year":2021,"lang":"en","type":"review","venue":"Journal of Market Access & Health Policy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"","keywords":"Reimbursement; Market access; Business; Product (mathematics); Process (computing); Medicine; Actuarial science; Operations management; Computer science; Economics; Health care; Economic growth","score_opus":0.5673573973348432,"score_gpt":0.5849998081847655,"score_spread":0.01764241084992224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193864401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002024198,0.8562139,0.00038694768,0.13619064,0.0008428162,0.0021239978,0.0002552348,0.000016617623,0.003767401],"genre_scores_gemma":[0.00019320213,0.95084614,0.002343392,0.0439877,0.0020668318,0.00026819838,0.00005326228,0.000113086324,0.00012819485],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9811201,0.0030666906,0.013870837,0.00073308096,0.0003073701,0.00090193894],"domain_scores_gemma":[0.9721886,0.0045022005,0.021071441,0.0007367357,0.0005678986,0.00093313877],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0231322,0.00053778925,0.0064991605,0.0038674953,0.0002667091,0.00039636256,0.0017350606,0.00035828125,0.0004312066],"category_scores_gemma":[0.023963826,0.0005083623,0.0002903531,0.0030635167,0.00007256566,0.0012615297,0.0004589435,0.0012430163,0.000092253365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000059344256,0.0005994579,0.009843135,0.025851395,0.00038343438,0.000070183,0.002871613,0.00013676901,7.1333477e-9,0.002834406,0.30312818,0.6542221],"study_design_scores_gemma":[0.0007391313,0.0004145414,0.00343684,0.014568724,0.00003416843,0.00018609011,0.0002171977,0.000040616356,2.720245e-8,0.00012882317,0.9798492,0.0003846065],"about_ca_topic_score_codex":0.0037447335,"about_ca_topic_score_gemma":0.002685865,"teacher_disagreement_score":0.67672104,"about_ca_system_score_codex":0.0046078465,"about_ca_system_score_gemma":0.013908051,"threshold_uncertainty_score":0.9997368},"labels":[],"label_agreement":null},{"id":"W4398182533","doi":"10.3390/jmahp12020009","title":"Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance","year":2024,"lang":"en","type":"review","venue":"Journal of Market Access & Health Policy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Protocol (science); Health technology; Critical appraisal; Medicine; Business; Political science; Alternative medicine; Health care","score_opus":0.6991957781312884,"score_gpt":0.6739127582861535,"score_spread":0.025283019845134924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398182533","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029181656,0.63449216,0.00025183705,0.3580988,0.0016284342,0.004568671,0.0005902231,0.00002905123,0.0003116651],"genre_scores_gemma":[0.00012030516,0.9514667,0.00719199,0.037305795,0.0022111086,0.00065624295,0.000016958655,0.00010935651,0.0009215364],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9531973,0.0065384563,0.036125094,0.0018566445,0.00077945064,0.0015030811],"domain_scores_gemma":[0.9468861,0.025991606,0.023017844,0.0018238458,0.00075430365,0.0015262523],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1214745,0.0008547012,0.010522902,0.0055059413,0.00029195944,0.00041140206,0.0026083714,0.00047690416,0.0007579806],"category_scores_gemma":[0.09826343,0.00089116534,0.0007435553,0.004361656,0.0002777912,0.0030382846,0.0010549104,0.0022467896,0.00020038488],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011964071,0.00023081288,0.0018627153,0.36866337,0.00037815387,0.000015315694,0.00047091013,0.0000028288987,2.2747056e-8,0.022905923,0.34932095,0.2549526],"study_design_scores_gemma":[0.0009458637,0.0009093253,0.00082474155,0.4207599,0.000120054785,0.000011548758,0.000060581482,0.000030942167,2.4445098e-8,0.0016825523,0.57423925,0.00041522508],"about_ca_topic_score_codex":0.022477677,"about_ca_topic_score_gemma":0.005833488,"teacher_disagreement_score":0.320793,"about_ca_system_score_codex":0.009484454,"about_ca_system_score_gemma":0.019821372,"threshold_uncertainty_score":0.9993539},"labels":[],"label_agreement":null},{"id":"W4400974639","doi":"10.3390/jmahp12030014","title":"Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison","year":2024,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Steno Diabetes Center Copenhagen; Bayer","keywords":"Canagliflozin; Medicine; Internal medicine; Type 2 diabetes; Confounding; Hazard ratio; Randomized controlled trial; Kidney disease; Diabetes mellitus; Confidence interval; Endocrinology","score_opus":0.03849699808939505,"score_gpt":0.3778843863415415,"score_spread":0.3393873882521464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400974639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887472,0.0045028804,0.0000032789621,0.005071009,0.00026447844,0.00067876425,0.000033810906,0.000016358264,0.00068221736],"genre_scores_gemma":[0.99853337,0.00048551828,0.00008798445,0.0004944869,0.00019984948,0.0000075045227,0.000043282664,0.000022086491,0.00012594779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828494,0.00015372732,0.00064148626,0.00018206863,0.00037809537,0.0003597123],"domain_scores_gemma":[0.9984957,0.0002426976,0.00041802254,0.00015873791,0.00012639194,0.00055842416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037621587,0.00020147527,0.0008425454,0.00078679976,0.00003874381,0.000051478033,0.00013528722,0.00003579737,0.000071429364],"category_scores_gemma":[0.00014148488,0.00014346131,0.00006141816,0.0007533923,0.00006425234,0.00023880089,0.00007661082,0.00027062904,0.0000017876216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015571277,0.0020814838,0.86455154,0.005910473,0.002175681,0.00007612511,0.001800664,0.00015644413,0.000004643145,0.00013669596,0.062096976,0.04543802],"study_design_scores_gemma":[0.011424132,0.003132956,0.9757545,0.0029327294,0.0003944352,5.6276457e-7,0.00004065207,0.0004875784,0.000011034431,0.00002390584,0.0056794933,0.00011799414],"about_ca_topic_score_codex":0.00079125445,"about_ca_topic_score_gemma":0.0004717631,"teacher_disagreement_score":0.11120301,"about_ca_system_score_codex":0.0007331494,"about_ca_system_score_gemma":0.0018438839,"threshold_uncertainty_score":0.5850182},"labels":[],"label_agreement":null},{"id":"W4401858295","doi":"10.3390/jmahp12030017","title":"Patient Experience and Satisfaction with Orthopedic Services at a Community (Rural) Setting Hospital—How Is It Different from Urban Setting","year":2024,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Patient Satisfaction in Healthcare","field":"Health Professions","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Patient satisfaction; Patient experience; Orthopedic surgery; Quality (philosophy); Health care; Work (physics); Medicine; Narrative; Nursing; Psychology","score_opus":0.044853196961646434,"score_gpt":0.4313270351385387,"score_spread":0.3864738381768923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401858295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91230386,0.0026850475,0.000053663345,0.081886165,0.0015017797,0.00101739,0.00026378845,0.00008918962,0.00019912286],"genre_scores_gemma":[0.9836605,0.0023294888,0.0003071126,0.012296882,0.0010323941,0.00011130502,0.000027517619,0.00006947847,0.00016530658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99282134,0.003249421,0.001704618,0.00034598616,0.00094162073,0.00093701866],"domain_scores_gemma":[0.99373794,0.0021348065,0.0023858044,0.000482624,0.00045346058,0.0008053428],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013336344,0.00042182032,0.0007242369,0.0005752828,0.0026282794,0.00018041412,0.00035171682,0.00024372793,0.0004889503],"category_scores_gemma":[0.00027592498,0.00031440108,0.00011013557,0.0005574115,0.00010575466,0.0015356599,0.0005074689,0.0025910267,0.0000098922055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020632833,0.000026590762,0.8338437,0.0028378118,0.00009207957,0.000012737579,0.09929029,0.0000016584062,0.000009340799,0.00001172295,0.026005087,0.03766266],"study_design_scores_gemma":[0.00080157863,0.0006963981,0.9437267,0.0075226943,0.000050748447,0.000040804953,0.034781687,0.00035701616,0.000011291775,0.00015332515,0.011572652,0.00028510223],"about_ca_topic_score_codex":0.047450572,"about_ca_topic_score_gemma":0.007335858,"teacher_disagreement_score":0.10988301,"about_ca_system_score_codex":0.0022924352,"about_ca_system_score_gemma":0.0011956394,"threshold_uncertainty_score":0.9999308},"labels":[],"label_agreement":null},{"id":"W4402185636","doi":"10.3390/jmahp12030020","title":"Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis","year":2024,"lang":"en","type":"article","venue":"Journal of Market Access & Health Policy","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Discontinuation; Atrial fibrillation; Medicine; Internal medicine; Cardiology","score_opus":0.04110476782569135,"score_gpt":0.4063531100015693,"score_spread":0.365248342175878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402185636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98307604,0.00004297275,0.0037921865,0.011983046,0.000096039206,0.00091141986,0.000018306957,0.000026801024,0.000053217373],"genre_scores_gemma":[0.9974235,0.00024090362,0.00010741959,0.00068815827,0.001203588,0.0000018713495,0.00023002096,0.00003267806,0.0000718515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965089,0.00048597038,0.0010650491,0.00024822197,0.001306968,0.0003849026],"domain_scores_gemma":[0.9978829,0.0006577196,0.0007635962,0.000225071,0.00022576214,0.00024492672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023680285,0.00025609747,0.00089266914,0.0022723218,0.00012883701,0.00026471564,0.0002105636,0.00009732559,0.00011433594],"category_scores_gemma":[0.00030028838,0.0001257859,0.0002706551,0.0037235504,0.000040357343,0.00056103815,0.000033587527,0.0003552339,9.919448e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004560802,0.000029384872,0.9791213,0.000277458,0.00081157574,0.00012035835,0.0005314258,0.0047333413,2.059257e-7,0.0000019023312,0.00035307967,0.009459156],"study_design_scores_gemma":[0.005086762,0.00097219343,0.89332473,0.0011753327,0.0009823273,0.00000716237,0.00014096244,0.09742306,0.0000014129865,0.0000047872877,0.00074916484,0.00013212695],"about_ca_topic_score_codex":0.0066340896,"about_ca_topic_score_gemma":0.0022714487,"teacher_disagreement_score":0.09268972,"about_ca_system_score_codex":0.00031564772,"about_ca_system_score_gemma":0.00088476634,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W4412693204","doi":"10.3390/jmahp13030038","title":"Patient Involvement in Health Technology Assessments: Lessons for EU Joint Clinical Assessments","year":2025,"lang":"en","type":"review","venue":"Journal of Market Access & Health Policy","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Agencia Española de Medicamentos y Productos Sanitarios; National Institute for Health and Care Excellence","keywords":"Health technology; European union; Best practice; Process (computing); Political science; Health care; Medicine; Process management; Public relations; Business; Knowledge management; Computer science; International trade","score_opus":0.7195339884714608,"score_gpt":0.6773990463529387,"score_spread":0.04213494211852209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412693204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012794807,0.7642648,0.0025636891,0.22413133,0.0025331287,0.004482374,0.0010207464,0.000027239172,0.0009638597],"genre_scores_gemma":[0.00003601854,0.9454492,0.006964753,0.04495975,0.0012579744,0.0006845649,0.00008715191,0.000100003956,0.00046061393],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9578865,0.004335999,0.034675244,0.0011506209,0.0003665353,0.0015850557],"domain_scores_gemma":[0.95104235,0.004229626,0.042483035,0.0010841041,0.00035303153,0.00080784754],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.08331088,0.00075917796,0.010918062,0.006741478,0.00034508662,0.00024645973,0.0016087174,0.0008603556,0.00015378896],"category_scores_gemma":[0.01161398,0.0008189453,0.0012786723,0.0017153989,0.00011918765,0.0007995446,0.0005397344,0.0019135801,0.00004238451],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000042728818,0.0009438739,0.0011285308,0.09545174,0.0005090407,0.0000045381835,0.00011097313,0.0000099898425,6.6426414e-10,0.036462445,0.23573801,0.62959814],"study_design_scores_gemma":[0.0016094332,0.0010938605,0.0008234405,0.031270776,0.000040807172,0.000021003321,0.00025269252,0.000100442354,8.723821e-9,0.008790476,0.95554984,0.00044721557],"about_ca_topic_score_codex":0.0025063918,"about_ca_topic_score_gemma":0.0005957312,"teacher_disagreement_score":0.71981186,"about_ca_system_score_codex":0.012296211,"about_ca_system_score_gemma":0.026201334,"threshold_uncertainty_score":0.9994261},"labels":[],"label_agreement":null}]}